Thu, Sep 18, 2014, 4:10 AM EDT - U.S. Markets open in 5 hrs 20 mins


% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

  • jeremybates15 jeremybates15 Jan 22, 2013 10:28 PM Flag

    new fact sheet on website

    There's a new fact sheet on the website. It says "Updated on January 15, 2013."

    The fact sheet asserts that the AEZS-108 trial in endometrial cancer has been "initiated." Their wording is "Pivotal Phase 3 trial initiated in Q1-2013 (not yet recruiting)."

    The perifosine interim analysis is still "expected in Q1-2013." And the AEZS-130 NDA is still "planned in Q1-2013."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • From the fact sheet:

      Perifosine (oral Akt inhibitor)
      FDA orphan-drug and Fast Track designations, as well as EMA positive Scientific Advice and orphan medicinal product designation.
       Multiple Myeloma
      - Ongoing Phase 3 trial in U.S. with additional sites in Europe and other countries
      - Interim analysis expected in Q1-2013

      AEZS-108 (doxorubicin peptide conjugate)
      Hybrid molecule composed of a synthetic peptide carrier linked to doxorubicin, specifically targeting LHRH receptor expressing tumors.
       Advanced Endometrial Cancer
      - Pivotal Phase 3 trial initiated in Q1-2013 (not yet recruiting)
       Advanced Ovarian Cancer
      - Phase 2 trial completed
       Castration- and Taxane-Resistant Prostate Cancer, Refractory Bladder Cancer and Triple Negative Breast Cancer
      - Ongoing Phase 2 trials

      AEZS-130 (oral ghrelin agonist)
      FDA orphan-drug designation as diagnostic test for growth hormone deficiency.
       Adult Growth Hormone Deficiency (AGHD)
      - Phase 3 trial completed as oral diagnostic test
      - NDA filing planned in Q1-2013
       Cancer-cachexia
      - Ongoing Phase 2A trial in the U.S.

      • 1 Reply to sprypoke
      • Bumping up.

        Three hugely positive events scheduled in the next two months.

        1. AEZS-130 - NDA filing planned in Q1-2013
        2. AEZS-108 - Pivotal Phase 3 trial initiated in Q1-2013. May be a partnership announcement any day.
        3. Perifosine - Interim analysis expected end of Q1-2013 or early April

        Easy double from here with very little risk if one gets out before Perifosine interim analysis. Will be a 4 or 5 bagger with a AEZS 108 partnership and successful Perifosine results.

        Sentiment: Strong Buy

1.41-0.02(-1.40%)Sep 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.